Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    GOG-0268
Show Display Options
Rank Status Study
1 Recruiting Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Stage III Ovarian Cancer;   Stage IV Ovarian Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Temsirolimus;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis
2 Completed Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
Conditions: Ovarian Neoplasms;   Breast Neoplasms
Intervention:

Indicates status has not been verified in more than two years